Innovent Biologics

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

China: The Innovation Factor – Implications for Pharma BD and Investors

6 min

China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.

Innovent Biologics Shares Surge 10% Following Pfizer Deal

2 min

Innovent Biologics' shares have surged by 10% following a major partnership with Pfizer valued at up to $10.5 billion. This article analyzes the market impact and future implications.

Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal

cancer · 2 min

Innovent Biologics and Pfizer have entered a significant $10.5 billion deal for a cancer drug, marking a pivotal moment in China's biotech landscape. This article explores the implications for the pharmaceutical industry.

Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights

cancer · 4 min

Pfizer and Innovent have entered a significant $10B deal focusing on cancer therapeutics. This article delves into the implications for the pharmaceutical landscape.

Innovent Biologics and Pfizer: A $10.5B Oncology Partnership

oncology · 2 min

Innovent Biologics has signed a landmark $10.5 billion deal with Pfizer to conduct 12 cancer drug trials. This partnership is set to significantly impact the oncology market.